Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis

Oliver A. Cornely, Lambertus Meems, Raoul Herbrecht, Claudio Viscoli, Ronald G M van Amsterdam, Markus Ruhnke

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Invasive aspergillosis remains associated with significant morbidity and mortality, necessitating new options for salvage therapy. The objective of this study was to evaluate the efficacy and safety of micafungin as salvage monotherapy in patients with invasive aspergillosis. Patients with proven or probable invasive aspergillosis, who were refractory or intolerant to previous systemic antifungal therapy, were randomised 2 : 1 to receive 300 mg day-1 intravenous micafungin monotherapy or an intravenous control monotherapy [lipid amphotericin B (5 mg kg-1 day-1), voriconazole (8 mg kg-1 day-1) or caspofungin (50 mg day-1)] for 3-12 weeks. Patients underwent final assessment 12 weeks after treatment start. Seventeen patients with invasive aspergillosis (proven, n = 2; probable, n = 14; not recorded, n = 1) participated in the study (micafungin arm, n = 12; control arm, n = 5). Three patients each in the micafungin (25.0%; 95% CI: 5.5-57.2) and control arm (60.0%; 95% CI: 14.7-94.7) had successful therapy at end of treatment as assessed by an Independent Data Review Board. Eleven patients died; six due to invasive aspergillosis. No deaths were considered related to study treatment. During this study it became increasingly common to use combination treatment for salvage therapy. Consequently, enrolment was low and the study was discontinued early. No clear trends in efficacy and safety can be concluded.

Original languageEnglish
Pages (from-to)58-64
Number of pages7
JournalMycoses
Volume58
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Salvage Therapy
Aspergillosis
Multicenter Studies
caspofungin
Therapeutics
Safety
Amphotericin B
micafungin
Morbidity
Lipids
Mortality

Keywords

  • Combination therapy
  • Invasive aspergillosis
  • Micafungin
  • Monotherapy
  • Salvage

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases
  • Medicine(all)

Cite this

Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. / Cornely, Oliver A.; Meems, Lambertus; Herbrecht, Raoul; Viscoli, Claudio; van Amsterdam, Ronald G M; Ruhnke, Markus.

In: Mycoses, Vol. 58, No. 1, 01.01.2015, p. 58-64.

Research output: Contribution to journalArticle

Cornely, Oliver A. ; Meems, Lambertus ; Herbrecht, Raoul ; Viscoli, Claudio ; van Amsterdam, Ronald G M ; Ruhnke, Markus. / Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. In: Mycoses. 2015 ; Vol. 58, No. 1. pp. 58-64.
@article{fe032f0f8b604335b78edf030d1ec6a1,
title = "Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis",
abstract = "Invasive aspergillosis remains associated with significant morbidity and mortality, necessitating new options for salvage therapy. The objective of this study was to evaluate the efficacy and safety of micafungin as salvage monotherapy in patients with invasive aspergillosis. Patients with proven or probable invasive aspergillosis, who were refractory or intolerant to previous systemic antifungal therapy, were randomised 2 : 1 to receive 300 mg day-1 intravenous micafungin monotherapy or an intravenous control monotherapy [lipid amphotericin B (5 mg kg-1 day-1), voriconazole (8 mg kg-1 day-1) or caspofungin (50 mg day-1)] for 3-12 weeks. Patients underwent final assessment 12 weeks after treatment start. Seventeen patients with invasive aspergillosis (proven, n = 2; probable, n = 14; not recorded, n = 1) participated in the study (micafungin arm, n = 12; control arm, n = 5). Three patients each in the micafungin (25.0{\%}; 95{\%} CI: 5.5-57.2) and control arm (60.0{\%}; 95{\%} CI: 14.7-94.7) had successful therapy at end of treatment as assessed by an Independent Data Review Board. Eleven patients died; six due to invasive aspergillosis. No deaths were considered related to study treatment. During this study it became increasingly common to use combination treatment for salvage therapy. Consequently, enrolment was low and the study was discontinued early. No clear trends in efficacy and safety can be concluded.",
keywords = "Combination therapy, Invasive aspergillosis, Micafungin, Monotherapy, Salvage",
author = "Cornely, {Oliver A.} and Lambertus Meems and Raoul Herbrecht and Claudio Viscoli and {van Amsterdam}, {Ronald G M} and Markus Ruhnke",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/myc.12274",
language = "English",
volume = "58",
pages = "58--64",
journal = "Mycoses",
issn = "0933-7407",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis

AU - Cornely, Oliver A.

AU - Meems, Lambertus

AU - Herbrecht, Raoul

AU - Viscoli, Claudio

AU - van Amsterdam, Ronald G M

AU - Ruhnke, Markus

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Invasive aspergillosis remains associated with significant morbidity and mortality, necessitating new options for salvage therapy. The objective of this study was to evaluate the efficacy and safety of micafungin as salvage monotherapy in patients with invasive aspergillosis. Patients with proven or probable invasive aspergillosis, who were refractory or intolerant to previous systemic antifungal therapy, were randomised 2 : 1 to receive 300 mg day-1 intravenous micafungin monotherapy or an intravenous control monotherapy [lipid amphotericin B (5 mg kg-1 day-1), voriconazole (8 mg kg-1 day-1) or caspofungin (50 mg day-1)] for 3-12 weeks. Patients underwent final assessment 12 weeks after treatment start. Seventeen patients with invasive aspergillosis (proven, n = 2; probable, n = 14; not recorded, n = 1) participated in the study (micafungin arm, n = 12; control arm, n = 5). Three patients each in the micafungin (25.0%; 95% CI: 5.5-57.2) and control arm (60.0%; 95% CI: 14.7-94.7) had successful therapy at end of treatment as assessed by an Independent Data Review Board. Eleven patients died; six due to invasive aspergillosis. No deaths were considered related to study treatment. During this study it became increasingly common to use combination treatment for salvage therapy. Consequently, enrolment was low and the study was discontinued early. No clear trends in efficacy and safety can be concluded.

AB - Invasive aspergillosis remains associated with significant morbidity and mortality, necessitating new options for salvage therapy. The objective of this study was to evaluate the efficacy and safety of micafungin as salvage monotherapy in patients with invasive aspergillosis. Patients with proven or probable invasive aspergillosis, who were refractory or intolerant to previous systemic antifungal therapy, were randomised 2 : 1 to receive 300 mg day-1 intravenous micafungin monotherapy or an intravenous control monotherapy [lipid amphotericin B (5 mg kg-1 day-1), voriconazole (8 mg kg-1 day-1) or caspofungin (50 mg day-1)] for 3-12 weeks. Patients underwent final assessment 12 weeks after treatment start. Seventeen patients with invasive aspergillosis (proven, n = 2; probable, n = 14; not recorded, n = 1) participated in the study (micafungin arm, n = 12; control arm, n = 5). Three patients each in the micafungin (25.0%; 95% CI: 5.5-57.2) and control arm (60.0%; 95% CI: 14.7-94.7) had successful therapy at end of treatment as assessed by an Independent Data Review Board. Eleven patients died; six due to invasive aspergillosis. No deaths were considered related to study treatment. During this study it became increasingly common to use combination treatment for salvage therapy. Consequently, enrolment was low and the study was discontinued early. No clear trends in efficacy and safety can be concluded.

KW - Combination therapy

KW - Invasive aspergillosis

KW - Micafungin

KW - Monotherapy

KW - Salvage

UR - http://www.scopus.com/inward/record.url?scp=84919468961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919468961&partnerID=8YFLogxK

U2 - 10.1111/myc.12274

DO - 10.1111/myc.12274

M3 - Article

VL - 58

SP - 58

EP - 64

JO - Mycoses

JF - Mycoses

SN - 0933-7407

IS - 1

ER -